Personnel Information

写真a

SHIMIZU Hideyuki


Job title

Professor

Research Areas, Keywords

artificial intelligence, machine learning, bioinformatics, clinical informatics

Field Introduction URL

Homepage (Dept. AI Systems Medicine)

Graduating School 【 display / non-display

  • Tohoku University, Faculty of Medicine, 2012.03, Graduated

Graduate School 【 display / non-display

  • Kyushu University, Doctor's Course, 2018.03, Accomplished credits for doctoral program

Campus Career 【 display / non-display

  • 2022.02
    -
    Now
    Tokyo Medical and Dental University, M&D Data Science Center, Division of Health Intelligence, Department of AI Systems Medicine, Professor

External Career 【 display / non-display

  • 2012.04
    -
    2014.03
    , Trainee Resident
  • 2020.10
    -
    2021.03
    , Project Assistant Professor
  • 2021.04
    -
    2022.01
    Harvard Medical School, Department of Systems Biology, Research Fellow
  • 2021.04
    -
    2022.01
    Wyss Institute for Biologically Inspired Engineering, Research Fellow

Research Areas 【 display / non-display

  • Applied molecular and cellular biology

  • Life, health and medical informatics

  • Pharmaceutical chemistry and drug development sciences

  • Mathematical informatics

Qualification Acquired 【 display / non-display

  • Doctor

 

Published Papers & Misc 【 display / non-display

  1. Kodama M, Toyokawa G, (20名省略), Bamba T, Shimizu H, Yoshizumi T, Nakayama KI. Modulation of host glutamine anabolism enhances the sensitivity of small cell lung cancer to chemotherapy Cell Reports. 2023.08; 42 (8): 112899.

  2. Fujinuma S, Nakatsumi H, Shimizu H, Sugiyama S, Harada A, Goya T, Tanaka M, Kohjima M, Takahashi M, Izumi Y, Yagi M, Kang D, Kaneko M, Shigeta M, Bamba T, Ohkawa Y, Nakayama KI. FOXK1 promotes nonalcoholic fatty liver disease by mediating mTORC1-dependent inhibition of hepatic fatty acid oxidation Cell Reports. 2023.05; 42 (5): 112530. ( DOI )

  3. Hozumi H, Shimizu H. Bayesian network enables interpretable and state-of-the-art prediction of immunotherapy responses in cancer patients PNAS Nexus. 2023.04; 2 (5): pgad133. ( PubMed, DOI )

  4. Shimizu H, Kodama M, Matsumoto M, Orba Y, Sasaki Y, Sato A, Sawa H, Nakayama KI. LIGHTHOUSE illuminates therapeutics for a variety of diseases including COVID-19 iScience. 2022.10; 25 (11): 105314. ( PubMed, DOI )

  5. Habara M, Sato Y, Goshima T, Sakurai M, Imai H, Shimizu H, Katayama Y, Hanaki S, Masaki T, Morimoto M, Nishikawa S, Toyama T, Shimada M. FKBP52 and FKBP51 Differentially Regulate the Stability of Estrogen Receptor in Breast Cancer Proc Natl Acad Sci U S A. 2022.04; 119 (15): e2110256119. ( PubMed, DOI )

  6. Mise S, Matsumoto A, Shimada K, Hosaka T, Takahashi M, Ichihara K, Shimizu H, Shiraishi C, Saito D, Suyama M, Yasuda T, Ide T, Izumi Y, Bamba T, Kimura-Someya T, Shirouzu M, Miyata H, Ikawa M, Nakayama KI. Kastor and Polluks polypeptides encoded by a single gene locus cooperatively regulate VDAC and spermatogenesis. Nature communications. 2022.02; 13 (1): 1071. ( PubMed, DOI )

  7. Ichihara K, Matsumoto A, Nishida H, Kito Y, Shimizu H, Shichino Y, Iwasaki S, Imami K, Ishihama Y, Nakayama KI. Combinatorial analysis of translation dynamics reveals eIF2 dependence of translation initiation at near-cognate codons Nucleic Acids Research. 2021.07; 49 (13): 7298-7317. ( PubMed, DOI )

  8. Shimizu H, Nakayama KI. A universal molecular prognostic score for gastrointestinal tumors. NPJ genomic medicine. 2021.02; 6 (1): 6. ( PubMed, DOI )

  9. Onoyama I, Nakayama S, Shimizu H, Nakayama KI. Loss of Fbxw7 Impairs Development of and Induces Heterogeneous Tumor Formation in the Mouse Mammary Gland. Cancer research. 2020.12; 80 (24): 5515-5530. ( PubMed, DOI )

  10. Yamauchi Y, Nita A, Nishiyama M, Muto Y, Shimizu H, Nakatsumi H, Nakayama KI.. Skp2 contributes to cell cycle progression in trophoblast stem cells and to placental development Genes Cells. 2020.06; 25 (6): 427-438. ( PubMed, DOI )

  11. Shimizu H, Nakayama KI. Artificial intelligence in oncology. Cancer science. 2020.05; 111 (5): 1452-1460. ( PubMed, DOI )

  12. Kodama M, Oshikawa K, Shimizu H, Yoshioka S, Takahashi M, Izumi Y, Bamba T, Tateishi C, Tomonaga T, Matsumoto M, Nakayama KI. A shift in glutamine nitrogen metabolism contributes to malignant progression of cancer Nature Communications. 2020.03; 11 (1320):

  13. Oshikawa K, Matsumoto M, Kodama M, Shimizu H, Nakayama KI. A fail-safe system to prevent oncogenesis by senescence is targeted by SV40 small T antigen. Oncogene. 2020.03; 39 (10): 2170-2186. ( PubMed, DOI )

  14. Shimizu H, Nakayama KI. A 23 gene-based molecular prognostic score precisely predicts overall survival of breast cancer patients. EBioMedicine. 2019.08; 46 150-159. ( PubMed, DOI )

  15. Muto Y, Moroishi T, Ichihara K, Nishiyama M, Shimizu H, Eguchi H, Moriya K, Koike K, Mimori K, Mori M, Katayama Y, Nakayama KI. Disruption of FBXL5-mediated cellular iron homeostasis promotes liver carcinogenesis Journal of Experimental Medicine. 2019.04; 216 (4): 950-965. ( PubMed, DOI )

  16. Shimizu H, Takeishi S, Nakatsumi H, Nakayama KI. Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells. JCI insight. 2019.02; 4 (4): ( PubMed, DOI )

  17. Yuriko Saiki, Yuki Yoshino, Hiroko Fujimura, Tatsuya Manabe, Yuki Kudo, Miki Shimada, Nariyasu Mano, Tomohiro Nakano, Yoonha Lee, Shinjiro Shimizu, Shinya Oba, Sho Fujiwara, Hideyuki Shimizu, Na Chen, Zhaleh Kashkouli Nezhad, Guo Jin, Shinichi Fukushige, Makoto Sunamura, Masaharu Ishida, Fuyuhiko Motoi, Shinichi Egawa, Michiaki Unno, Akira Horii. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells Biochem Biophys Res Commun.. 2012.04; 421 (1): 98-104. ( PubMed, DOI )

  18. Shimizu H, Horii A, Sunamura M, Motoi F, Egawa S, Unno M, Fukushige S. Identification of epigenetically silenced genes in human pancreatic cancer by a novel method "microarray coupled with methyl-CpG targeted transcriptional activation" (MeTA-array) Biochem Biophys Res Commun.. 2011.07; 411 (1): 162-167. ( PubMed, DOI )

▼display all

Conference Activities & Talks 【 display / non-display

  1. Hideyuki SHIMIZU. Toward personalized cancer treatment through AI drug discovery. 2023.09

  2. Hideyuki Shimizu. Toward ultra-fast drug discovery for hundreds of pathogens. Japan America Frontiers of Engineering 2023.07

  3. Hideyuki SHIMIZU. Future challenges of AI in oncology. Chugai Cancer Summit 2023.06

  4. 清水秀幸. 臨床応用を目指したデータ科学・AI創薬研究. 東北大学主催第1回医学AIセミナー 2023.04

  5. 清水秀幸. データサイエンスによる小細胞肺がん治療法の確立を目指して. 15th NUJRA special seminar 2023.03

  6. 清水 秀幸. Machine learning uncovers novel aspects in healthcare and life science. 第42回 日本分子生物学会年会 シンポジウム 2019.12.04

  7. 清水 秀幸. An AI-based Scoring System Precisely Predicts Overall Survival of Breast Cancer Patients. 第14回研究所ネットワーク国際シンポジウム 2019.10.02

▼display all

 

Performance of duties 【 display / non-display

  • ,2012.04 - Now